Fertility Outcomes in Risdiplam-Treated Male Patients with Spinal Muscular Atrophy: A Multicenter Case Series
This series presents three cases of successful conception while a male patient was receiving risdiplam, a US Food and Drug Administration-approved treatment for SMA. Although there were reproductive concerns due to impairment in spermatogenesis that arose during nonclinical studies, this case series demonstrates that there was sufficient sperm production while on risdiplam to result in pregnancy. More research is needed to provide a complete understanding of the effects of risdiplam on male fertility in humans. Graphical abstract available for this article.
Authors
- Margaret R. Frey
- Michael Lopez (ORCID: https://orcid.org/0009-0001-5691-5272)
- Marcus Erdler
- Shelley Coskery
Institutions
- Donauspital (AT)
- Children's of Alabama (US)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1007/s12325-025-03171-1
- Citations
- 6
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 9.75
Funders
- Genentech Foundation
- Genentech